Br J Pharmacol  Br. J. Pharmacol  10.1111/(ISSN)1476-5381  BPH  British Journal of Pharmacology   0007-1188  1476-5381  John Wiley and Sons Inc.  Hoboken    6844537  10.1111/bph.14747  BPH14747  10.1111/bph.14747  The Concise Guide to Pharmacology 2019/20   The Concise Guide to Pharmacology 2019/20    THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets   Alexander  Stephen PH   https://orcid.org/0000-0003-4417-497X  1    Kelly  Eamonn   2    Mathie  Alistair   https://orcid.org/0000-0001-6094-2890  3    Peters  John A   https://orcid.org/0000-0002-4277-4245  4    Veale  Emma L   https://orcid.org/0000-0002-6778-9929  3    Armstrong  Jane F   https://orcid.org/0000-0002-0524-0260  5    Faccenda  Elena   https://orcid.org/0000-0001-9855-7103  5    Harding  Simon D   https://orcid.org/0000-0002-9262-8318  5    Pawson  Adam J   https://orcid.org/0000-0003-2280-845X  5    Sharman  Joanna L   https://orcid.org/0000-0002-5275-6446  5    Southan  Christopher   https://orcid.org/0000-0001-9580-0446  5    Buneman  O Peter   6    Cidlowski  John A   https://orcid.org/0000-0003-1420-0516  7    Christopoulos  Arthur   https://orcid.org/0000-0003-4442-3294  8    Davenport  Anthony P   https://orcid.org/0000-0002-2096-3117  9    Fabbro  Doriano   https://orcid.org/0000-0002-9400-4517  10    Spedding  Michael   https://orcid.org/0000-0002-1248-8221  11    Striessnig  Jörg   https://orcid.org/0000-0002-9406-7120  12    Davies  Jamie A   https://orcid.org/0000-0001-6660-4032  5    CGTP Collaborators    Arumugam  Thiruma V   13    Bennett  Andrew   14    Sjögren  Benita   https://orcid.org/0000-0003-1460-1045  15    Sobey  Christopher   https://orcid.org/0000-0001-6525-9097  16    Wong  Szu Shen   17     1   School of Life Sciences  University of Nottingham Medical School  Nottingham  NG7 2UH  UK   2   School of Physiology, Pharmacology and Neuroscience  University of Bristol  Bristol  BS8 1TD  UK   3   Medway School of Pharmacy  The Universities of Greenwich and Kent at Medway  Anson Building, Central Avenue, Chatham Maritime  Chatham  Kent  ME4 4TB  UK   4   Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School  University of Dundee  Dundee  DD1 9SY  UK   5   Centre for Discovery Brain Sciences  University of Edinburgh  Edinburgh  EH8 9XD  UK   6   Laboratory for Foundations of Computer Science, School of Informatics  University of Edinburgh  Edinburgh  EH8 9LE  UK   7   National Institute of Environmental Health Sciences  National Institutes of Health, Department of Health and Human Services  Research Triangle Park  NC  27709  USA   8   Monash Institute of Pharmaceutical Sciences and Department of Pharmacology  Monash University  Parkville  Victoria  3052  Australia   9   Clinical Pharmacology Unit  University of Cambridge  Cambridge  CB2 0QQ  UK   10   PIQUR Therapeutics  Basel  4057  Switzerland   11   Spedding Research Solutions SARL  Le Vésinet  78110  France   12   Pharmacology and Toxicology, Institute of Pharmacy  University of Innsbruck  A-6020  Innsbruck  Austria   13   Singapore  Singapore   14   Nottingham  UK   15   West Lafayette  USA   16   Clayton  Australia   17   Keele  UK   11  11  2019   12  2019   11  11  2019   176  Suppl 1  10.1111/bph.v176.S1  S1  S20  © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.  This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.       The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands ( http://www.guidetopharmacology.org/ ), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at  http://onlinelibrary.wiley.com/doi/10.1111/bph.14747 . In addition to this overview, in which are identified Other protein targets which fall outside of the subsequent categorisation, there are six areas of focus: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate. 

               source-schema-version-number  2.0   cover-date  December 2019   details-of-publishers-convertor  Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:11.11.2019     Stephen PH  Alexander  ,  Eamonn  Kelly  ,  Alistair  Mathie  ,  John A  Peters  ,  Emma L  Veale  ,  Elena  Faccenda  ,  Simon D  Harding  ,  Adam J  Pawson  ,  Joanna L  Sharman  ,  Christopher  Southan  ,  O Peter  Buneman  ,  John A  Cidlowski  ,  Arthur  Christopoulos  ,  Anthony P  Davenport  ,  Doriano  Fabbro  ,  Michael  Spedding  ,  Jörg  Striessnig  ,  Jamie A  Davies  and  CGTP Collaborators (  2019 )  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets .  British Journal of Pharmacology ,  176 :  S1 –  S20 . doi:  10.1111/bph.14747 .  

   1  Table of contents  S1 Introduction and Other Protein Targets  S6 Adiponectin receptors   S7 Blood coagulation components   S8 Non‐enzymatic BRD containing proteins   S9 Carrier proteins   S9 CD molecules   S11 Methyllysine reader proteins   S11 Fatty acid‐binding proteins   S14 Notch receptors   S15 Regulators of G protein Signaling (RGS) proteins

  S18 Sigma receptors   S19 Tubulins   

  S21 G protein‐coupled receptors  S23 Orphan and other 7TM receptors   S24 Class A Orphans   S26 Class C Orphans   S33 Taste 1 receptors   S34 Taste 2 receptors   S35 Other 7TM proteins   S36 5‐Hydroxytryptamine receptors   S39 Acetylcholine receptors (muscarinic)   S41 Adenosine receptors   S42 Adhesion Class GPCRs   S45 Adrenoceptors   S48 Angiotensin receptors   S50 Apelin receptor   S51 Bile acid receptor   S51 Bombesin receptors   S53 Bradykinin receptors   S54 Calcitonin receptors   S56 Calcium‐sensing receptor   S57 Cannabinoid receptors   S58 Chemerin receptors   S59 Chemokine receptors   S63 Cholecystokinin receptors   S64 Class Frizzled GPCRs   S67 Complement peptide receptors   S68 Corticotropin‐releasing factor receptors   S69 Dopamine receptors   S71 Endothelin receptors   S72 G protein‐coupled estrogen receptor   S73 Formylpeptide receptors   S74 Free fatty acid receptors   S76 GABA B receptors    S78 Galanin receptors   S79 Ghrelin receptor   S80 Glucagon receptor family   S81 Glycoprotein hormone receptors   S82 Gonadotrophin‐releasing hormone receptors   S83 GPR18, GPR55 and GPR119   S84 Histamine receptors   S86 Hydroxycarboxylic acid receptors   S87 Kisspeptin receptor   S88 Leukotriene receptors   S89 Lysophospholipid (LPA) receptors   S90 Lysophospholipid (S1P) receptors   S92 Melanin‐concentrating hormone receptors   S93 Melanocortin receptors   S94 Melatonin receptors   S95 Metabotropic glutamate receptors   S97 Motilin receptor   S98 Neuromedin U receptors   S99 Neuropeptide FF/neuropeptide AF receptors   S100 Neuropeptide S receptor   S101 Neuropeptide W/neuropeptide B receptors   S102 Neuropeptide Y receptors   S103 Neurotensin receptors   S104 Opioid receptors   S106 Orexin receptors   S107 Oxoglutarate receptor   S108 P2Y receptors   S110 Parathyroid hormone receptors   S111 Platelet‐activating factor receptor   S112 Prokineticin receptors   S113 Prolactin‐releasing peptide receptor   S114 Prostanoid receptors   S116 Proteinase‐activated receptors   S117 QRFP receptor   S118 Relaxin family peptide receptors   S120 Somatostatin receptors   S121 Succinate receptor   S122 Tachykinin receptors   S123 Thyrotropin‐releasing hormone receptors   S124 Trace amine receptor   S125 Urotensin receptor   S126 Vasopressin and oxytocin receptors   S127 VIP and PACAP receptors   

  S142 Ion channels  S143 Ligand‐gated ion channels   S144 5‐HT 3 receptors    S146 Acid‐sensing (proton‐gated) ion channels (ASICs)

  S148 Epithelial sodium channel (ENaC)   S149 GABA A receptors    S155 Glycine receptors   S158 Ionotropic glutamate receptors   S164 IP 3 receptor    S165 Nicotinic acetylcholine receptors   S168 P2X receptors   S170 ZAC   S171 Voltage‐gated ion channels   S171 CatSper and Two‐Pore channels   S173 Cyclic nucleotide‐regulated channels   S175 Potassium channels   S175 Calcium‐ and sodium‐activated potassium channels

  S178 Inwardly rectifying potassium channels   S182 Two P domain potassium channels   S185 Voltage‐gated potassium channels   S189 Ryanodine receptors   S190 Transient Receptor Potential channels   S204 Voltage‐gated calcium channels   S207 Voltage‐gated proton channel   S208 Voltage‐gated sodium channels   S210 Other ion channels   S210 Aquaporins   S212 Chloride channels   S213 ClC family   S215 CFTR   S216 Calcium activated chloride channel   S217 Maxi chloride channel   S218 Volume regulated chloride channels   S219 Connexins and Pannexins   S221 Piezo channels   S222 Sodium leak channel, non‐selective   

  S229 Nuclear hormone receptors  S230 1A. Thyroid hormone receptors   S231 1B. Retinoic acid receptors   S232 1C. Peroxisome proliferator‐activated receptors

  S233 1D. Rev‐Erb receptors   S234 1F. Retinoic acid‐related orphans   S234 1H. Liver X receptor‐like receptors   S235 1I. Vitamin D receptor‐like receptors   S236 2A. Hepatocyte nuclear factor‐4 receptors   S237 2B. Retinoid X receptors   S238 2C. Testicular receptors   S238 2E. Tailless‐like receptors   S239 2F. COUP‐TF‐like receptors   S239 3B. Estrogen‐related receptors   S240 4A. Nerve growth factor IB‐like receptors   S241 5A. Fushi tarazu F1‐like receptors   S241 6A. Germ cell nuclear factor receptors   S242 0B. DAX‐like receptors   S242 Steroid hormone receptors   S243 3A. Estrogen receptors   S244 3C. 3‐Ketosteroid receptors   

  S247 Catalytic receptors  S248 Cytokine receptor family   S249 IL‐2 receptor family   S251 IL‐3 receptor family   S252 IL‐6 receptor family   S254 IL‐12 receptor family   S255 Prolactin receptor family   S256 Interferon receptor family   S257 IL‐10 receptor family   S258 Immunoglobulin‐like family of IL‐1 receptors   S259 IL‐17 receptor family   S259 GDNF receptor family   S260 Integrins   S264 Pattern recognition receptors   S264 Toll‐like receptor family   S266 NOD‐like receptor family   S268 RIG‐I‐like receptor family   S269 Receptor Guanylyl Cyclase (RGC) family   S269 Transmembrane quanylyl cyclases   S270 Nitric oxide (NO)‐sensitive (soluble) guanylyl cyclase

  S271 Receptor tyrosine kinases (RTKs)   S272 Type I RTKs: ErbB (epidermal growth factor) receptor family

  S273 Type II RTKs: Insulin receptor family   S274 Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family

  S275 Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family

  S275 Type V RTKs: FGF (broblast growth factor) receptor family

  S276 Type VI RTKs: PTK7/CCK4   S277 Type VII RTKs: Neurotrophin receptor/Trk family

  S278 Type VIII RTKs: ROR family   S278 Type IX RTKs: MuSK   S279 Type X RTKs: HGF (hepatocyte growth factor) receptor family

  S279 Type XI RTKs: TAM (TYRO3‐, AXL‐ and MER‐TK) receptor family

  S280 Type XII RTKs: TIE family of angiopoietin receptors

  S280 Type XIII RTKs: Ephrin receptor family   S281 Type XIV RTKs: RET   S282 Type XV RTKs: RYK   S282 Type XVI RTKs: DDR (collagen receptor) family

  S283 Type XVII RTKs: ROS receptors   S283 Type XVIII RTKs: LMR family   S284 Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family

  S284 Type XX RTKs: STYK1   S286 Receptor serine/threonine kinase (RSTK) family

  S286 Type I receptor serine/threonine kinases   S287 Type II receptor serine/threonine kinases   S287 Type III receptor serine/threonine kinases   S287 RSTK functional heteromers   S289 Receptor tyrosine phosphatase (RTP) family   S291 Tumour necrosis factor (TNF) receptor family   

  S297 Enzymes  S301 Acetylcholine turnover   S302 Adenosine turnover   S303 Amino acid hydroxylases   S304 L‐Arginine turnover   S304 2.1.1.‐ Protein arginine N‐methyltransferases

  S305 Arginase   S305 Arginine:glycine amidinotransferase   S305 Dimethylarginine dimethylaminohydrolases   S306 Nitric oxide synthases   S307 Carbonic anhydrases   S308 Carboxylases and decarboxylases   S308 Carboxylases   S309 Decarboxylases   S311 Catecholamine turnover   S313 Ceramide turnover   S313 Serine palmitoyltransferase   S314 Ceramide synthase   S314 Sphingolipid Δ 4 ‐desaturase    S315 Sphingomyelin synthase   S315 Sphingomyelin phosphodiesterase   S316 Neutral sphingomyelinase coupling factors   S316 Ceramide glucosyltransferase   S316 Acid ceramidase   S317 Neutral ceramidases   S317 Alkaline ceramidases   S318 Ceramide kinase   S319 Chromatin modifying enzymes   S319 2.1.1.‐ Protein arginine N‐methyltransferases

  S320 3.5.1.‐ Histone deacetylases (HDACs)   S321 Cyclic nucleotide turnover/signalling   S321 Adenylyl cyclases (ACs)   S323 Exchange protein activated by cyclic AMP (EPACs)

  S323 Phosphodiesterases, 3’,5’‐cyclic nucleotide (PDEs)

  S327 Cytochrome P450   S327 CYP2 family   S328 CYP2 family   S329 CYP3 family   S330 CYP4 family   S331 CYP5, CYP7 and CYP8 families   S332 CYP11, CYP17, CYP19, CYP20 and CYP21 families

  S333 CYP24, CYP26 and CYP27 families   S333 CYP39, CYP46 and CYP51 families   S334 DNA topoisomerases   S335 Endocannabinoid turnover   S336 N ‐Acylethanolamine turnover    S337 2‐Acylglycerol ester turnover   S338 Eicosanoid turnover   S338 Cyclooxygenase   S339 Prostaglandin synthases   S341 Lipoxygenases   S342 Leukotriene and lipoxin metabolism   S343 GABA turnover   S344 Glycerophospholipid turnover   S345 Phosphoinositide‐specific phospholipase C   S346 Phospholipase A 2    S348 Phosphatidylcholine‐specific phospholipase D   S349 Lipid phosphate phosphatases   S349 Phosphatidylinositol kinases   S350 1‐phosphatidylinositol 4‐kinase family   S351 Phosphatidylinositol‐4‐phosphate 3‐kinase family

  S351 Phosphatidylinositol 3‐kinase family   S351 Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase family

  S352 1‐phosphatidylinositol‐3‐phosphate 5‐kinase family

  S353 Type I PIP kinases (1‐phosphatidylinositol‐4‐phosphate 5‐kinase family)

  S353 Type II PIP kinases (1‐phosphatidylinositol‐5‐phosphate 4‐kinase family)

  S356 Phosphatidylinositol phosphate kinases   S356 Haem oxygenase   S358 Hydrogen sulphide synthesis   S358 Hydrolases   S360 Inositol phosphate turnover   S360 Inositol 1,4,5‐trisphosphate 3‐kinases   S360 Inositol polyphosphate phosphatases   S361 Inositol monophosphatase   S361 Kinases (EC 2.7.x.x)   S362 Rho kinase   S362 Protein kinase C (PKC) family   S363 Alpha subfamily   S363 Delta subfamily   S364 Eta subfamily   S364 FRAP subfamily   S365 Cyclin‐dependent kinase (CDK) family   S365 CDK4 subfamily   S366 GSK subfamily   S367 Polo‐like kinase (PLK) family   S367 STE7 family   S368 Abl family   S368 Ack family   S369 Janus kinase (JakA) family   S369 Src family   S370 Tec family   S371 RAF family   S372 Lanosterol biosynthesis pathway   S374 Nucleoside synthesis and metabolism   S376 Paraoxonase (PON) family   S377 Peptidases and proteinases   S377 A1: Pepsin   S377 A22: Presenilin   S378 C14: Caspase   S378 M1: Aminopeptidase N   S379 M2: Angiotensin‐converting (ACE and ACE2)   S379 M10: Matrix metallopeptidase   S380 M12: Astacin/Adamalysin   S380 M28: Aminopeptidase Y   S381 M19: Membrane dipeptidase   S381 S1: Chymotrypsin   S382 T1: Proteasome   S382 S8: Subtilisin   S383 S9: Prolyl oligopeptidase   S383 Poly ADP‐ribose polymerases   S384 Prolyl hydroxylases   S384 Sphingosine 1‐phosphate turnover   S385 Sphingosine kinase   S386 Sphingosine 1‐phosphate phosphatase   S387 Sphingosine 1‐phosphate lyase   S387 Thyroid hormone turnover   S388 1.14.13.9 Kynurenine 3‐monooxygenase   S389 2.5.1.58 Protein farnesyltransferase   S390 3.5.1.‐ Histone deacetylases (HDACs)   S391 3.5.3.15 Peptidyl arginine deiminases (PADI)   S391 3.6.5.2 Small monomeric GTPases   S391 RAS subfamily   S392 RAB subfamily   

  S397 Transporters  S399 ATP‐binding cassette transporter family   S399 ABCA subfamily   S401 ABCB subfamily   S403 ABCC subfamily   S404 ABCD subfamily of peroxisomal ABC transporters

  S405 ABCG subfamily   S406 F‐type and V‐type ATPases   S406 F‐type ATPase   S407 V‐type ATPase   S407 P‐type ATPases   S407 Na + /K  + ‐ATPases    S408 Ca 2+ ‐ATPases    S408 H + /K  + ‐ATPases    S408 Cu + ‐ATPases    S409 Phospholipid‐transporting ATPases   S409 SLC superfamily of solute carriers   S410 SLC1 family of amino acid transporters   S410 Glutamate transporter subfamily   S412 Alanine/serine/cysteine transporter subfamily

  S413 SLC2 family of hexose and sugar alcohol transporters

  S413 Class I transporters   S414 Class II transporters   S415 Proton‐coupled inositol transporter   S415 SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)

  S415 SLC3 family   S416 SLC7 family   S417 SLC4 family of bicarbonate transporters   S417 Anion exchangers   S418 Sodium‐dependent HCO 3  − transporters    S418 SLC5 family of sodium‐dependent glucose transporters

  S419 Hexose transporter family   S420 Choline transporter   S421 Sodium iodide symporter, sodium‐dependent multivitamin transporter and sodium‐coupled monocarboxylate transporters

  S422 Sodium myo ‐inositol cotransporter transporters 

  S423 SLC6 neurotransmitter transporter family   S423 Monoamine transporter subfamily   S424 GABA transporter subfamily   S425 Glycine transporter subfamily   S427 Neutral amino acid transporter subfamily   S428 SLC8 family of sodium/calcium exchangers   S429 SLC9 family of sodium/hydrogen exchangers   S429 SLC10 family of sodium‐bile acid co‐transporters

  S431 SLC11 family of proton‐coupled metal ion transporters

  S431 SLC12 family of cation‐coupled chloride transporters

  S433 SLC13 family of sodium‐dependent sulphate/carboxylate transporters

  S434 SLC14 family of facilitative urea transporters

  S435 SLC15 family of peptide transporters   S437 SLC16 family of monocarboxylate transporters   S438 SLC17 phosphate and organic anion transporter family

  S438 Type I sodium‐phosphate co‐transporters   S439 Sialic acid transporter   S439 Vesicular glutamate transporters (VGLUTs)   S440 Vesicular nucleotide transporter   S440 SLC18 family of vesicular amine transporters   S442 SLC19 family of vitamin transporters   S443 SLC20 family of sodium‐dependent phosphate transporters

  S443 SLC22 family of organic cation and anion transporters

  S444 Organic cation transporters (OCT)   S445 Organic zwitterions/cation transporters (OCTN)

  S446 Organic anion transporters (OATs)   S446 Urate transporter   S447 Atypical SLC22B subfamily   S448 SLC23 family of ascorbic acid transporters   S449 SLC24 family of sodium/potassium/calcium exchangers

  S450 SLC25 family of mitochondrial transporters   S450 Mitochondrial di‐ and tri‐carboxylic acid transporter subfamily

  S451 Mitochondrial amino acid transporter subfamily

  S452 Mitochondrial phosphate transporters   S452 Mitochondrial nucleotide transporter subfamily

  S453 Mitochondrial uncoupling proteins   S454 Miscellaneous SLC25 mitochondrial transporters

  S454 SLC26 family of anion exchangers   S454 Selective sulphate transporters   S455 Chloride/bicarbonate exchangers   S455 Anion channels   S456 Other SLC26 anion exchangers   S457 SLC27 family of fatty acid transporters   S458 SLC28 and SLC29 families of nucleoside transporters

  S458 SLC28 family   S459 SLC29 family   S461 SLC30 zinc transporter family   S461 SLC31 family of copper transporters   S462 SLC32 vesicular inhibitory amino acid transporter

  S463 SLC33 acetylCoA transporter   S464 SLC34 family of sodium phosphate co‐transporters

  S465 SLC35 family of nucleotide sugar transporters

  S466 SLC36 family of proton‐coupled amino acid transporters

  S468 SLC37 family of phosphosugar/phosphate exchangers

  S468 SLC38 family of sodium‐dependent neutral amino acid transporters

  S469 System A‐like transporters   S469 System N‐like transporters   S470 Orphan SLC38 transporters   S470 SLC39 family of metal ion transporters   S471 SLC40 iron transporter   S472 SLC41 family of divalent cation transporters   S473 SLC42 family of Rhesus glycoprotein ammoniumtransporters

  S473 SLC43 family of large neutral amino acid transporters

  S474 SLC44 choline transporter‐like family   S475 SLC45 family of putative sugar transporters   S475 SLC46 family of folate transporters   S477 SLC47 family of multidrug and toxin extrusion transporters

  S477 SLC48 heme transporter   S478 SLC49 family of FLVCR‐related heme transporters

  S479 SLC50 sugar transporter   S479 SLC51 family of steroid‐derived molecule transporters

  S480 SLC52 family of riboflavin transporters   S481 SLC53 Phosphate carriers   S481 SLC54 Mitochondrial pyruvate carriers   S482 SLC55 Mitochondrial cation/proton exchangers   S482 SLC56 Sideroflexins   S483 SLC57 NiPA‐like magnesium transporter family   S483 SLC58 MagT‐like magnesium transporter family   S484 SLC59 Sodium‐dependent lysophosphatidylcholine symporter family

  S484 SLC60 Glucose transporters   S485 SLC61 Molybdate transporter family   S485 SLC62 Pyrophosphate transporters   S486 SLC63 Sphingosine phosphate transporters   S486 SLC64 Golgi Ca2+/H+ exchangers   S487 SLC65 NPC‐type cholesterol transporters   S488 SLCO family of organic anion transporting polypeptides

  

   Introduction  In order to allow clarity and consistency in pharmacology, there is a need for a comprehensive organisation and presentation of the targets of drugs. This is the philosophy of the IUPHAR/BPS Guide to PHARMACOLOGY presented on the online free access database ( https://www.guidetopharmacology.org/ ). This database is supported by the British Pharmacological Society (BPS), the International Union of Basic and Clinical Pharmacology (IUPHAR), the University of Edinburgh and previously the Wellcome Trust. Data included in the Guide to PHARMACOLOGY are derived in large part from interactions with the subcommittees of the Nomenclature Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR). A major influence on the development of the database was Tony Harmar (1951‐2014), who worked with a passion to establish the curators as a team of highly informed and informative individuals, with a focus on high‐quality data input, ensuring a suitably validated dataset. The Editors of the Concise Guide have compiled the individual records, in concert with the team of Curators, drawing on the expert knowledge of these latter subcommittees. The tables allow an indication of the status of the nomenclature for the group of targets listed, usually previously published in Pharmacological Reviews. In the absence of an established subcommittee, advice from several prominent, independent experts has generally been obtained to produce an authoritative consensus on nomenclature, which attempts to fit in within the general guidelines from NC‐IUPHAR. This current edition, the Concise Guide to PHARMACOLOGY 2019/20, is the latest snapshot of the database in print form, following on from the Concise Guide to PHARMACOLOGY 2017/18. It contains data drawn from the online database as a rapid overview of the major pharmacological targets. Thus, there are many fewer targets presented in the Concise Guide compared to the online database. The priority for inclusion in the Concise Guide is the presence of quantitative pharmacological data for human proteins. This means that often orphan family members are not presented in the Concise Guide, although structural information is available on the online database. The organisation of the data is tabular (where appropriate) with a standardised format, where possible on a single page, intended to aid understanding of, and comparison within, a particular target group. The Concise Guide is intended as an initial resource, with links to additional reviews and resources for greater depth and information. Pharmacological and structural data focus primarily on human gene products, wherever possible, with links to HGNC gene nomenclature and UniProt IDs. In a few cases, where data from human proteins are limited, data from other species are indicated. Pharmacological tools listed are prioritised on the basis of selectivity and availability. That is, agents (agonists, antagonists, inhibitors, activators, etc.) are included where they are both available (by donation or from commercial sources, now or in the near future) AND the most selective. The Concise Guide is divided into seven sections, which comprise pharmacological targets of similar structure/function. These are G protein‐coupled receptors, ion channels (combining previous records of ligand‐gated, voltage‐gated and other ion channels), catalytic receptors, nuclear hormone receptors, enzymes, transporters and other protein targets. We hope that the Concise Guide will provide for researchers, teachers and students a state‐of‐the art source of accurate, curated information on the background to their work that they will use in the Introductions to their Research Papers or Reviews, or in supporting their teaching and studies. We recommend that any citations to information in the Concise Guide are presented in the following format: Alexander SPH et al. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol 176: S1–S20. In this overview are listed protein targets of pharmacological interest, which are not G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, transporters or enzymes. 

  Acknowledgements  We are extremely grateful to the British Pharmacological Society and the International Union of Basic and Clinical Pharmacology, for financial support of the website and for advice from the NC‐IUPHAR subcommittees. We thank the University of Edinburgh, who host the http://www.guidetopharmacology.org website. Previously, the International Union of Basic and Clinical Pharmacology and the Wellcome Trust (099156/Z/12/Z]) also supported the initiation and expansion of the database. We are also tremendously grateful to the long list of collaborators from NC‐IUPHAR subcommittees and beyond, who have assisted in the construction of the Concise Guide to PHARMACOLOGY 2019/20 and the online database  http://www.guidetopharmacology.org . 

  Conflict of interest  The authors state that there are no conflicts of interest to disclose.

  Family structure  – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1021 

 S6 Adiponectin receptors   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=982 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=983 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=971 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=910 

 S7 Blood coagulation components   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=866 

 S8 Non‐enzymatic BRD containing proteins   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=966 

 S8 Carrier proteins   S9 CD molecules   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=997 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=998 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=986 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=901 

 S11 Methyllysine reader proteins   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=916 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=930 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=915 

 S11 Fatty acid-binding proteins   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=946 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=935 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=784 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=954 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=949 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=985 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=987 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=984 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=868 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=889 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=876 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=888 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=934 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=924 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=919 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=921 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=991 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=941 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=942 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=945 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=929 

 S14 Notch receptors   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1001 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=906 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=907 

 S15 Regulators of G protein Signaling (RGS) proteins 

 S15 RZ family   S15 R4 family   S16 R7 family   S17 R12 family   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=932 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=905 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=875 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1000 

 S18 Sigma receptors   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=989 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=972 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1019 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=973 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=974 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=990 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=995 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=996 

 S19 Tubulins   – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=904 

 – http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=903 

  http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=106   Overview  Adiponectin receptors ( provisional nomenclature ,  http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00500000270960 ) respond to the 30 kDa complement‐related protein hormone adiponectin (also known as  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633 : adipocyte, C1q and collagen domain‐containing protein; ACRP30, adipose most abundant gene transcript 1; apM‐1; gelatin‐binding protein:  http://www.uniprot.org/uniprot/Q15848 ) originally cloned from adipocytes [  http://www.ncbi.nlm.nih.gov/pubmed/8619847?dopt=AbstractPlus ]. Although sequence data suggest 7TM domains, immunological evidence indicates that, contrary to typical 7TM topology, the carboxyl terminus is extracellular, while the amino terminus is intracellular [  http://www.ncbi.nlm.nih.gov/pubmed/12802337?dopt=AbstractPlus ]. Signalling through these receptors appears to avoid G proteins; modelling based on the crystal structures of the adiponectin receptors suggested ceramidase acivity, which would make these the first in a new family of catalytic receptors [  http://www.ncbi.nlm.nih.gov/pubmed/25855295?dopt=AbstractPlus ].        Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=649 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=650 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24040 ,  http://www.uniprot.org/uniprot/Q96A54 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24041 ,  http://www.uniprot.org/uniprot/Q86V24 



 Rank order of potency  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3727 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633 ,  http://www.uniprot.org/uniprot/Q15848 ) >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633 ,  http://www.uniprot.org/uniprot/Q15848 ) 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3727 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633 ,  http://www.uniprot.org/uniprot/Q15848 ) =  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633 ,  http://www.uniprot.org/uniprot/Q15848 ) 



 

 

  Comments  T‐Cadherin ( https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1753 ,  http://www.uniprot.org/uniprot/P55290 ) has also been suggested to be a receptor for (hexameric) adiponectin [  http://www.ncbi.nlm.nih.gov/pubmed/15210937?dopt=AbstractPlus ]. 

  Further reading on Adiponectin receptors  Fisman EZ et al . (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?  Cardiovasc Diabetol  13 : 103 [  https://www.ncbi.nlm.nih.gov/pubmed/24957699?dopt=AbstractPlus ] 

 Okada‐Iwabu M et al . (2018) Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity.  Endocr J  65 : 971‐977 [  https://www.ncbi.nlm.nih.gov/pubmed/30282888 ] 

 Ruan H et al . (2016) Adiponectin signaling and function in insulin target tissues.  J Mol Cell Biol  8 : 101‐9 [  https://www.ncbi.nlm.nih.gov/pubmed/26993044?dopt=AbstractPlus ] 

 Wang Y et al . (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification.  Trends Endocrinol. Metab.  28 : 519‐530 [  https://www.ncbi.nlm.nih.gov/pubmed/28473178?dopt=AbstractPlus ] 

 Zhao L et al . (2014) Adiponectin and insulin cross talk: the microvascular connection.  Trends Cardiovasc. Med.  24 : 319‐24 [  https://www.ncbi.nlm.nih.gov/pubmed/25220977?dopt=AbstractPlus ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=853   Overview  Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel‐like clot local to the site of injury. The process involves the activation, adhesion (see http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=760 ), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms from less active precursors, typically through proteolysis (see  http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=759&familyType=ENZYME ). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.          Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2606 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3542 ,  http://www.uniprot.org/uniprot/P12259 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3546 ,  http://www.uniprot.org/uniprot/P00451 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:775 ,  http://www.uniprot.org/uniprot/P01008 



 Selective activators  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214 (p  K  d 7.8) [  http://www.ncbi.nlm.nih.gov/pubmed/23598032?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6819 (p  K  d 7.5) [  http://www.ncbi.nlm.nih.gov/pubmed/12383040?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6803 [  http://www.ncbi.nlm.nih.gov/pubmed/3744129?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6804 [  http://www.ncbi.nlm.nih.gov/pubmed/8137606?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/19398784?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811 [  http://www.ncbi.nlm.nih.gov/pubmed/7667822?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6846 [  http://www.ncbi.nlm.nih.gov/pubmed/7528134?dopt=AbstractPlus ] 



 Selective inhibitors  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788 (Antithrombotic effect thought to occur via inhibition of factors Va and VIIIa) [  http://www.ncbi.nlm.nih.gov/pubmed/11714212?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/11463021?dopt=AbstractPlus ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788 (Antithrombotic effect thought to occur via inhibition of factors Va and VIIIa) [  http://www.ncbi.nlm.nih.gov/pubmed/11714212?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/11463021?dopt=AbstractPlus ] 

 – 

 

 

  Further reading on Blood coagulation components  Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood  125 : 2045‐51 [  https://www.ncbi.nlm.nih.gov/pubmed/25712994?dopt=AbstractPlus ] 

 Girolami A et al . (2017) New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice.  J. Thromb. Thrombolysis  44 : 71‐75 [  https://www.ncbi.nlm.nih.gov/pubmed/28251495?dopt=AbstractPlus ] 

 Rana K et al . (2016) Blood flow and mass transfer regulation of coagulation.  Blood Rev.  30 : 357‐68 [  https://www.ncbi.nlm.nih.gov/pubmed/27133256?dopt=AbstractPlus ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=867   Overview  Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain‐containing proteins for which sufficient pharmacology exists.             Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2721 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2722 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2734 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2738 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2740 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:962 ,  http://www.uniprot.org/uniprot/Q9UIF9 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:963 ,  http://www.uniprot.org/uniprot/Q9UIF8 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348 ,  http://www.uniprot.org/uniprot/Q92793 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30064 ,  http://www.uniprot.org/uniprot/Q86U86 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11100 ,  http://www.uniprot.org/uniprot/P51532 



 Selective inhibitors  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233 (p  K  d 6.6) [  85 ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233 (Binding) (p  K  d 6.9) [  85 ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8236 (p  K  d 6.8) [  84 ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915 (Binding) (p  K  d 7.3) [  95 ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915 (Binding) (p  K  d 7.1) [  95 ] 



 

 

  Further reading on Non‐enzymatic BRD containing proteins  Fujisawa T et al . (2017) Functions of bromodomain‐containing proteins and their roles in homeostasis and cancer.  Nat. Rev. Mol. Cell Biol.  18 : 246‐262 [  https://www.ncbi.nlm.nih.gov/pubmed/28053347?dopt=AbstractPlus ] 

 Myrianthopoulos V & Mikros E. (2019) From bench to bedside, via desktop. Recent advances in the application of cutting‐edge in silico tools in the research of drugs targeting bromodomain modules. Biochem Pharmacol  159 : 40‐51 [  https://www.ncbi.nlm.nih.gov/pubmed/30414936 ] 

 Nicholas DA et al . (2017) BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.  Cell. Mol. Life Sci.  74 : 231‐243 [  https://www.ncbi.nlm.nih.gov/pubmed/27491296?dopt=AbstractPlus ] 

 Ramadoss M & Mahadevan V. (2018) Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today  23 : 76‐89 [  https://www.ncbi.nlm.nih.gov/pubmed/28943305 ] 

 Yang CY et al . (2019) Small‐molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins ‐ A review.  Drug Discov Today Technol  31 : 43‐51 [  https://www.ncbi.nlm.nih.gov/pubmed/31200858 ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=911   Overview  Transthyretin (TTR) is a homo‐tetrameric protein which transports thyroxine in the plasma and cerebrospinal fluid and retinol (vitamin A) in the plasma. Many disease causing mutations in the protein have been reported, many of which cause complex dissociation and protein mis‐assembly and deposition of toxic aggregates amyloid fibril formation [ http://www.ncbi.nlm.nih.gov/pubmed/23716704?dopt=AbstractPlus ]. These amyloidogenic mutants are linked to the development of pathological amyloidoses, including familial amyloid polyneuropathy (FAP) [  http://www.ncbi.nlm.nih.gov/pubmed/12978172?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/8894411?dopt=AbstractPlus ], familial amyloid cardiomyopathy (FAC) [  http://www.ncbi.nlm.nih.gov/pubmed/9017939?dopt=AbstractPlus ], amyloidotic vitreous opacities, carpal tunnel syndrome [  http://www.ncbi.nlm.nih.gov/pubmed/10403814?dopt=AbstractPlus ] and others. In old age, non‐mutated TTR can also form pathological amyloid fibrils [  http://www.ncbi.nlm.nih.gov/pubmed/7016817?dopt=AbstractPlus ]. Pharmacological intervention to reduce or prevent TTR dissociation is being pursued as a theapeutic strategy. To date one small molecule kinetic stabilising molecule (  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8378 ) has been approved for FAP, and is being evaluated in clinical trials for other TTR amyloidoses.      Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2851 



 Common abbreviation  TTR   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12405 ,  http://www.uniprot.org/uniprot/P02766 



 

 

  Further reading on Carrier proteins  Adams D et al . (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.  Nat Rev Neurol  15 : 387‐404 [  https://www.ncbi.nlm.nih.gov/pubmed/31209302 ] 

 Dellière S et al . (2017) Is transthyretin a good marker of nutritional status?  Clin Nutr  36 : 364‐370 [  https://www.ncbi.nlm.nih.gov/pubmed/27381508?dopt=AbstractPlus ] 

 Galant NJ et al . (2017) Transthyretin amyloidosis: an under‐recognized neuropathy and cardiomyopathy.  Clin. Sci.  131 : 395‐409 [  https://www.ncbi.nlm.nih.gov/pubmed/28213611?dopt=AbstractPlus ] 

 Yokoyama T & Mizuguchi M. (2018) Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds. Biol Pharm Bull  41 : 979‐984 [  https://www.ncbi.nlm.nih.gov/pubmed/29962408 ] 

 Ruberg FL et al . (2019) Transthyretin Amyloid Cardiomyopathy: JACC State‐of‐the‐Art Review.  J Am Coll Cardiol  73 : 2872‐2891 [  https://www.ncbi.nlm.nih.gov/pubmed/31171094 ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852   Overview  Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell‐surface proteins associated with immunotyping. Many members of the group have identified functions as enzymes (for example, see http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232 ) or receptors (for example, see  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2441 ). Many CDs are targeted for therapeutic gain using antibodies for the treatment of proliferative disorders. A full listing of all the Clusters of Differentiation proteins is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targeted for therapeutic gain.              Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2600 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2742 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2917 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 ) 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2601 



 Common abbreviation  –  –  –  –  SIGLEC‐3   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1639 ,  http://www.uniprot.org/uniprot/P06729 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1674 ,  http://www.uniprot.org/uniprot/P07766 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1691 ,  http://www.uniprot.org/uniprot/P30203 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7315 ,  http://www.uniprot.org/uniprot/P11836 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1659 ,  http://www.uniprot.org/uniprot/P20138 



 Selective inhibitors  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6787 [  http://www.ncbi.nlm.nih.gov/pubmed/11970990?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/12089534?dopt=AbstractPlus ] 

 –  –  –  – 

 Antibodies  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7385 (Binding) [  http://www.ncbi.nlm.nih.gov/pubmed/20190561?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889 (Binding) [  http://www.ncbi.nlm.nih.gov/pubmed/3105134?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8458 (Binding) [  http://www.ncbi.nlm.nih.gov/pubmed/8436176?dopt=AbstractPlus ] 

 –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6778 (Binding) (p  K  d 9.9) [  52 ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6780 (Binding) (p  K  d 8.5) [  http://www.ncbi.nlm.nih.gov/pubmed/15102696?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6777 (Binding),  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6941 (Binding) [  http://www.ncbi.nlm.nih.gov/pubmed/21378274?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/23537278?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6781 (Binding) 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7983 (Binding) (p  K  d ∼10) [  http://www.ncbi.nlm.nih.gov/pubmed/1458463?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6775 (Binding) [  http://www.ncbi.nlm.nih.gov/pubmed/10720144?dopt=AbstractPlus ] 



 

                Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2602 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2744 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2745 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 ) 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760 ) 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2918 



 Common abbreviation  –  –  –  CTLA‐4  PD‐1  –   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1804 ,  http://www.uniprot.org/uniprot/P31358 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700 ,  http://www.uniprot.org/uniprot/P33681 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705 ,  http://www.uniprot.org/uniprot/P42081 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2505 ,  http://www.uniprot.org/uniprot/P16410 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8760 ,  http://www.uniprot.org/uniprot/Q15116 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19319 ,  http://www.uniprot.org/uniprot/Q9UGN4 



 Endogenous ligands  –  –  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9606 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635 ,  https://www.uniprot.org/uniprot/Q9NZQ7 ) (Binding) 

 – 

 Selective inhibitors  –  abatacept (p K  d ∼7.9) [  51 ,  103 ]   abatacept (p K d ∼7.9) [  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6891 ], belatacept [  44 ] 

 –  –  – 

 Antibodies  alemtuzumab ( http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6770 ,  86 ] 

 –  –  ipilimumab (Binding) ( http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6888 ) [  30 ], tremelimumab (Binding) (  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8462 ] 

 pembrolizumab (Binding) (p K  d  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499 (Binding) (p  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499  d 9.1) [  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7335 ] 

 – 

 

 

  Comments  The endogenous ligands for human PD‐1 are programmed cell death 1 ligand 1 (PD‐L1 aka  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7693 (  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635 ,  http://www.uniprot.org/uniprot/Q9NZQ7 )) and programmed cell death 1 ligand 2 (PD‐L2;  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18731 ). These ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD‐1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti‐PD‐1 monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re‐establishing immune vigilance.  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499 was the first anti‐PD‐1 antibody to be approved by the US FDA. 

  Further reading on CD molecules  Gabius HJ et al . (2015) The glycobiology of the CD system: a dictionary for translating marker designations into glycan/lectin structure and function.  Trends Biochem. Sci.  40 : 360‐76 [  https://www.ncbi.nlm.nih.gov/pubmed/25981696?dopt=AbstractPlus ] 

 Vosoughi T et al . (2019) CD markers variations in chronic lymphocytic leukemia: New insights into prognosis.  J Cell Physiol .  234 : 19420‐39 [  https://www.ncbi.nlm.nih.gov/pubmed/31049958 ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=902   Overview  Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.     Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2830 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23035 ,  http://www.uniprot.org/uniprot/Q96JM7 



 Selective agonists  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8232 [  http://www.ncbi.nlm.nih.gov/pubmed/23292653?dopt=AbstractPlus ] 



 

 

  Further reading on Methyllysine reader proteins  Daskalaki MG et al . (2018) Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses.  J Cell Physiol .  233 : 6495‐9507 [  https://www.ncbi.nlm.nih.gov/pubmed/29574768 ] 

 Furuya K et al . (2019) Epigenetic interplays between DNA demethylation and histone methylation for protecting oncogenesis.  J Biochem .  165 : 297‐299 [  https://www.ncbi.nlm.nih.gov/pubmed/30605533 ] 

 Levy D. (2019) Lysine methylation signaling of non‐histone proteins in the nucleus. Cell Mol Life Sci  76 : 2873‐83 [  https://www.ncbi.nlm.nih.gov/pubmed/31123776 ] 

 Li J et al . (2019) Understanding histone H3 lysine 36 methylation and its deregulation in disease.  Cell Mol Life Sci in press [  https://www.ncbi.nlm.nih.gov/pubmed/31147750 ] 

 Shafabakhsh R et al . (2019) Role of histone modification and DNA methylation in signaling pathways involved in diabetic retinopathy.  J Cell Physiol.  234 : 7839‐7846 [  https://www.ncbi.nlm.nih.gov/pubmed/30515789 ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=783   Overview  Fatty acid‐binding proteins are low molecular weight (100‐130 aa) chaperones for long chain fatty acids, fatty acyl CoA esters, eicosanoids, retinols, retinoic acids and related metabolites and are usually regarded as being responsible for allowing the otherwise hydrophobic ligands to be mobile in aqueous media. These binding proteins may perform functions extracellularly ( e.g. in plasma) or transport these agents; to the nucleus to interact with nuclear receptors (principally PPARs and retinoic acid receptors  http://www.ncbi.nlm.nih.gov/pubmed/17882463?dopt=AbstractPlus ]) or for interaction with metabolic enzymes. Although sequence homology is limited, crystallographic studies suggest conserved 3D structures across the group of binding proteins.              Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2531 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2532 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2533 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2534 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2535 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3555 ,  http://www.uniprot.org/uniprot/P07148 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3556 ,  http://www.uniprot.org/uniprot/P12104 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3557 ,  http://www.uniprot.org/uniprot/P05413 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3559 ,  http://www.uniprot.org/uniprot/P15090 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3560 ,  http://www.uniprot.org/uniprot/Q01469 



 Rank order of potency  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 [  http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 [  http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 [  http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 [  http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus ] 

 – 

 Inhibitors  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7186 (p  K  i 7.6) [  http://www.ncbi.nlm.nih.gov/pubmed/18533710?dopt=AbstractPlus ] – Rat,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2662 (p  K  i 6.5) [  http://www.ncbi.nlm.nih.gov/pubmed/18533710?dopt=AbstractPlus ] – Rat,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6736 (p  K  i 5.1) [  http://www.ncbi.nlm.nih.gov/pubmed/19754198?dopt=AbstractPlus ] – Mouse 

 –  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8797 (p  K  i 8.7) [  http://www.ncbi.nlm.nih.gov/pubmed/17502136?dopt=AbstractPlus ] 



 Selective inhibitors  –  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8788 (p  K  i >9) [  http://www.ncbi.nlm.nih.gov/pubmed/21481589?dopt=AbstractPlus ] 

 – 

 Comments  A broader substrate specificity than other FABPs, binding two fatty acids per protein [ http://www.ncbi.nlm.nih.gov/pubmed/9054409?dopt=AbstractPlus ]. 

 Crystal structure of the rat FABP2 [ http://www.ncbi.nlm.nih.gov/pubmed/2671390?dopt=AbstractPlus ]. 

 Crystal structure of the human FABP3 [ http://www.ncbi.nlm.nih.gov/pubmed/7922029?dopt=AbstractPlus ]. 

 –  Crystal structure of the human FABP5 [ http://www.ncbi.nlm.nih.gov/pubmed/10493790?dopt=AbstractPlus ]. 



 

              Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2536 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2537 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2544 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2538 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2584 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3561 ,  http://www.uniprot.org/uniprot/P51161 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3562 ,  http://www.uniprot.org/uniprot/O15540 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9117 ,  http://www.uniprot.org/uniprot/P02689 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3563 ,  http://www.uniprot.org/uniprot/Q0Z7S8 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:34524 ,  http://www.uniprot.org/uniprot/A6NFH5 



 Comments  Able to transport bile acids [ http://www.ncbi.nlm.nih.gov/pubmed/23603607?dopt=AbstractPlus ]. 

 Crystal structure of the human FABP7 [ http://www.ncbi.nlm.nih.gov/pubmed/10854433?dopt=AbstractPlus ]. 

 In silico modelling suggests that PMP2/FABP8 can bind both fatty acids and cholesterol [  http://www.ncbi.nlm.nih.gov/pubmed/20421974?dopt=AbstractPlus ]. 

 –  – 

 

                  Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2546 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2547 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2548 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2549 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2550 

   http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2551 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9919 ,  http://www.uniprot.org/uniprot/P09455 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9920 ,  http://www.uniprot.org/uniprot/P50120 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9921 ,  http://www.uniprot.org/uniprot/P10745 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9922 ,  http://www.uniprot.org/uniprot/P02753 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15847 ,  http://www.uniprot.org/uniprot/P82980 

   https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30316 ,  http://www.uniprot.org/uniprot/Q96R05 



 Rank order of potency  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 [  http://www.ncbi.nlm.nih.gov/pubmed/10852718?dopt=AbstractPlus ] 

 –  –  –  –   

 Inhibitors  –  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8792 (pIC  50 7.8) [  http://www.ncbi.nlm.nih.gov/pubmed/24835984?dopt=AbstractPlus ] 

 –  –   

 

          Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2545 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2529 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2530 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10024 ,  http://www.uniprot.org/uniprot/P12271 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2338 ,  http://www.uniprot.org/uniprot/P29762 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2339 ,  http://www.uniprot.org/uniprot/P29373 



 Rank order of potency  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6669 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6670 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6673 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6671 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6672 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2350 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053 [  http://www.ncbi.nlm.nih.gov/pubmed/9541407?dopt=AbstractPlus ] 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377 >  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 [  http://www.ncbi.nlm.nih.gov/pubmed/10852718?dopt=AbstractPlus ] 

 – 

 

 

  Comments  Although not tested at all FABPs, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6735 exhibits high affinity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [  http://www.ncbi.nlm.nih.gov/pubmed/17554340?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/17502136?dopt=AbstractPlus ].  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6736 is reported to interfere with FABP4 action [  http://www.ncbi.nlm.nih.gov/pubmed/19754198?dopt=AbstractPlus ]. Ibuprofen displays some selectivity for FABP4 (pIC  50 5.5) relative to FABP3 (pIC  50 3.5) and FABP5 (pIC  50 3.8) [  http://www.ncbi.nlm.nih.gov/pubmed/24248795?dopt=AbstractPlus ]. Fenofibric acid displays some selectivity for FABP5 (pIC  50 5.5) relative to FABP3 (pIC  50 4.5) and FABP4 (pIC  50 4.6) [  http://www.ncbi.nlm.nih.gov/pubmed/24248795?dopt=AbstractPlus ]. Multiple pseudogenes for the FABPs have been identified in the human genome. 

  Further reading on Fatty acid‐binding proteins  Gajda AM et al . (2015) Enterocyte fatty acid‐binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine.  Prostaglandins Leukot. Essent. Fatty Acids  93 : 9‐16 [  https://www.ncbi.nlm.nih.gov/pubmed/25458898?dopt=AbstractPlus ] 

 Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent Fatty Acids  93 : 45‐9 [  https://www.ncbi.nlm.nih.gov/pubmed/25154384?dopt=AbstractPlus ] 

 Hotamisligil GS et al . (2015) Metabolic functions of FABPs–mechanisms and therapeutic implications.  Nat Rev Endocrinol  11 : 592‐605 [  https://www.ncbi.nlm.nih.gov/pubmed/26260145?dopt=AbstractPlus ] 

 Matsumata M et al . (2016) Fatty acid binding proteins and the nervous system: Their impact on mental conditions.  Neurosci. Res.  102 : 47‐55 [  https://www.ncbi.nlm.nih.gov/pubmed/25205626?dopt=AbstractPlus ] 

 Osumi T et al . (2016) Heart lipid droplets and lipid droplet‐binding proteins: Biochemistry, physiology, and pathology.  Exp. Cell Res.  340 : 198‐204 [  https://www.ncbi.nlm.nih.gov/pubmed/26524506?dopt=AbstractPlus ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=914   Overview  The canonical Notch signalling pathway has four type I transmembrane Notch receptors (Notch1‐4) and five ligands (DLL1, 2 and 3, and Jagged 1‐2). Each member of this highly conserved receptor family plays a unique role in cell‐fate determination during embryogenesis, differentiation, tissue patterning, proliferation and cell death [ http://www.ncbi.nlm.nih.gov/pubmed/20971825?dopt=AbstractPlus ]. As the Notch ligands are also membrane bound, cells have to be in close proximity for receptorligand interactions to occur. Cleavage of the intracellular domain (ICD) of activated Notch receptors by γ‐secretase is required for downstream signalling and Notch‐induced transcriptional modulation [  http://www.ncbi.nlm.nih.gov/pubmed/10206645?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/16530044?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/9620803?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/16530045?dopt=AbstractPlus ]. This is why γ‐secretase inhibitors can be used to downregulate Notch signalling and explains their anticancer action. One such small molecule is  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7338 [  http://www.ncbi.nlm.nih.gov/pubmed/19773430?dopt=AbstractPlus ], although development of this compound has been terminated following an unsuccessful Phase II single agent clinical trial in metastatic colorectal cancer [  http://www.ncbi.nlm.nih.gov/pubmed/22445247?dopt=AbstractPlus ]. 

 Aberrant Notch signalling is implicated in a number of human cancers [ http://www.ncbi.nlm.nih.gov/pubmed/17344417?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/24651013?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/18079963?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/17173050?dopt=AbstractPlus ], with  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8451 and  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8453 identified as antibody inhibitors of ligand:receptor binding [  http://www.ncbi.nlm.nih.gov/pubmed/25388163?dopt=AbstractPlus ].            Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2861 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2859 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2860 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2862 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7881 ,  http://www.uniprot.org/uniprot/P46531 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7882 ,  http://www.uniprot.org/uniprot/Q04721 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7883 ,  http://www.uniprot.org/uniprot/Q9UM47 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7884 ,  http://www.uniprot.org/uniprot/Q99466 



 Comments  Various types of activating and inactivating NOTCH1 mutations have been reported to be associated with human diseases, for example: aortic valve disease [  http://www.ncbi.nlm.nih.gov/pubmed/16025100?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/18593716?dopt=AbstractPlus ], Adams‐Oliver syndrome 5 [  http://www.ncbi.nlm.nih.gov/pubmed/25132448?dopt=AbstractPlus ], T‐cell acute lymphoblastic leukemia (T‐ALL) [  http://www.ncbi.nlm.nih.gov/pubmed/15472075?dopt=AbstractPlus ], chronic lymphocytic leukemia (CLL) [  http://www.ncbi.nlm.nih.gov/pubmed/21642962?dopt=AbstractPlus ] and head and neck squamous cell carcinoma [  http://www.ncbi.nlm.nih.gov/pubmed/21798897?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/21798893?dopt=AbstractPlus ]. 

 –  –  Notch receptor 4 is a potential therapeutic molecular target for triple‐negative breast cancer [ http://www.ncbi.nlm.nih.gov/pubmed/25993190?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/24403446?dopt=AbstractPlus ]. 



 

 

  Further reading on Notch receptors  Arumugam TV et al . (2018) Notch signaling and neuronal death in stroke.  Prog. Neurobiol.  165‐167 : 103‐116 [  https://www.ncbi.nlm.nih.gov/pubmed/29574014?dopt=AbstractPlus ] 

 Borggrefe T et al . (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways.  Biochim. Biophys. Acta  1863 : 303‐13 [  https://www.ncbi.nlm.nih.gov/pubmed/26592459?dopt=AbstractPlus ] 

 Palmer WH et al . (2015) Ligand‐Independent Mechanisms of Notch Activity.  Trends Cell Biol.  25 : 697‐707 [  https://www.ncbi.nlm.nih.gov/pubmed/26437585?dopt=AbstractPlus ] 

 Previs RA et al . (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.  Clin. Cancer Res.  21 : 955‐61 [  https://www.ncbi.nlm.nih.gov/pubmed/25388163?dopt=AbstractPlus ] 

 Takebe N et al . (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.  Nat Rev Clin Oncol  12 : 445‐64 [  https://www.ncbi.nlm.nih.gov/pubmed/25850553?dopt=AbstractPlus ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=891   Overview  Regulators of G protein signalling (RGS) proteins display a common RGS domain that interacts with the GTP‐bound Gα subunits of heterotrimeric G proteins, enhancing GTP hydrolysis by stabilising the transition state [ http://www.ncbi.nlm.nih.gov/pubmed/8756726?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/9108480?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/9417641?dopt=AbstractPlus ], leading to a termination of GPCR signalling. Interactions through protein: protein interactions of many RGS proteins have been identified for targets other than heteromeric G proteins. Sequence analysis of the 20 RGS proteins suggests four families of RGS: RZ, R4, R7 and R12 families. Many of these proteins have been identified to have effects other than through targetting G proteins. Included here is RGS4 for which a number of pharmacological inhibitors have been described. 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=892   Overview  The RZ family of RGS proteins is less well characterized than the other families [ http://www.ncbi.nlm.nih.gov/pubmed/16765607?dopt=AbstractPlus ]. It consists of RGS17 (also known as RGSZ2), RGS19 (also known as GAIP) and RGS20 (with several splice variants including RGSZ1 and Ret‐RGS). All members contain an N‐terminal cysteine string motif [  http://www.ncbi.nlm.nih.gov/pubmed/17183362?dopt=AbstractPlus ] which is a site of palmitoylation and could serve functions in membrane targeting, protein stability or aid protein‐protein interactions [  http://www.ncbi.nlm.nih.gov/pubmed/17126529?dopt=AbstractPlus ]. However, the function in the case of RZ family RGS proteins is not yet fully understood. Members of the RZ family of RGS proteins are the only RGS proteins that have selective GTPase activating‐protein (GAP) activity for Gα  z , a function that resulted in the name of the family [  http://www.ncbi.nlm.nih.gov/pubmed/9748279?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/15096504?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/9748280?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/1347957?dopt=AbstractPlus ]. However, the members of the RZ family are able to also GAP Gα  i/o members with varying selectivity.          Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2801 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2802 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2803 



 Common abbreviation  RGS17  RGS19  RGS20   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14088 ,  http://www.uniprot.org/uniprot/Q9UGC6 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13735 ,  http://www.uniprot.org/uniprot/P49795 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14600 ,  http://www.uniprot.org/uniprot/O76081 



 

 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=893   Overview  This is the largest family of RGS proteins.           Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2804 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2808 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2810 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811 



 Common abbreviation  RGS1  RGS2  RGS3  RGS4   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9991 ,  http://www.uniprot.org/uniprot/Q08116 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9998 ,  http://www.uniprot.org/uniprot/P41220 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9999 ,  http://www.uniprot.org/uniprot/P49796 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10000 ,  http://www.uniprot.org/uniprot/P49798 



 Selective inhibitors  –  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8033 (pIC  50 7.8) [  http://www.ncbi.nlm.nih.gov/pubmed/22368763?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7784 (pIC  50 7.5) [  http://www.ncbi.nlm.nih.gov/pubmed/21329361?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8034 (pIC  50 7.3) [  http://www.ncbi.nlm.nih.gov/pubmed/22368763?dopt=AbstractPlus ] 



 

                Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2812 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2805 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2806 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2807 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2809 



 Common abbreviation  RGS5  RGS8  RGS13  RGS16  RGS18  RGS21 

 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10001 ,  http://www.uniprot.org/uniprot/O15539 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16810 ,  http://www.uniprot.org/uniprot/P57771 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9995 ,  http://www.uniprot.org/uniprot/O14921 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9997 ,  http://www.uniprot.org/uniprot/O15492 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14261 ,  http://www.uniprot.org/uniprot/Q9NS28 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26839 ,  http://www.uniprot.org/uniprot/Q2M5E4 



 

 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=894   Overview  This family of RGS proteins shows some selectivity for Gai/o proteins.           Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2815 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2816 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2817 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2814 



 Common abbreviation  RGS6  RGS7  RGS9  RGS11   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10002 ,  http://www.uniprot.org/uniprot/P49758 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10003 ,  http://www.uniprot.org/uniprot/P49802 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10004 ,  http://www.uniprot.org/uniprot/O75916 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9993 ,  http://www.uniprot.org/uniprot/O94810 



 

 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=895   Overview  The R12 family consists of RGS10, 12 and 14. RGS12 and 14 are large proteins with additional domains that can participate in protein‐protein interactions and other functions. In contrast, RGS10 is a small protein consisting of the RGS domain and small N‐ and C‐termini, similar to members of the R4 family. However, sequence homology of the RGS10 RGS domain clearly places it in the R12 family [ http://www.ncbi.nlm.nih.gov/pubmed/26123306?dopt=AbstractPlus ]. The Gα  i/o ‐Loco (GoLoco) motif in RGS12 and 14 has GDI activity (for Guanine nucleotide Dissociation Inhibitor) towards Gα  i1 , Gα  i2 and Gα  i3 [  http://www.ncbi.nlm.nih.gov/pubmed/11387333?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/15951850?dopt=AbstractPlus ]. Through this activity RGS12 and RGS14 can inhibit G protein signaling both by accelerating GTP hydrolysis and by preventing G protein activation. Splice variants of RGS12 and RGS14 also contain membrane targeting and protein‐protein interaction domains [  http://www.ncbi.nlm.nih.gov/pubmed/11130074?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/11771424?dopt=AbstractPlus ,  http://www.ncbi.nlm.nih.gov/pubmed/9651375?dopt=AbstractPlus ].          Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2818 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2819 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2820 



 Common abbreviation  RGS10  RGS12  RGS14   HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9992 ,  http://www.uniprot.org/uniprot/O43665 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9994 ,  http://www.uniprot.org/uniprot/O14924 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9996 ,  http://www.uniprot.org/uniprot/O43566 



 

 

  Further reading on Regulators of G protein Signaling (RGS) proteins  Alqinyah M et al . (2018) Regulating the regulators: Epigenetic, transcriptional, and post‐translational regulation of RGS proteins.  Cell. Signal.  42 : 77‐87 [  https://www.ncbi.nlm.nih.gov/pubmed/29042285?dopt=AbstractPlus ] 

 Neubig RR et al . (2002) Regulators of G‐protein signalling as new central nervous system drug targets.  Nat Rev Drug Discov  1 : 187‐97 [  https://www.ncbi.nlm.nih.gov/pubmed/12120503?dopt=AbstractPlus ] 

 Sethakorn N et al . (2010) Non‐canonical functions of RGS proteins.  Cell. Signal.  22 : 1274‐81 [  https://www.ncbi.nlm.nih.gov/pubmed/20363320?dopt=AbstractPlus ] 

 Sjögren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets ‐ 20 years in the making: IUPHAR Review 21. Br. J. Pharmacol.  174 : 427‐437 [  https://www.ncbi.nlm.nih.gov/pubmed/28098342?dopt=AbstractPlus ] 

 Sjögren B et al . (2010) Thinking outside of the ‘RGS box’: new approaches to therapeutic targeting of regulators of G protein signaling.  Mol. Pharmacol.  78 : 550‐7 [  https://www.ncbi.nlm.nih.gov/pubmed/20664002?dopt=AbstractPlus ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=785   Overview  Although termed ’receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest pharmacological overlap and no structural convergence with the G protein‐coupled receptors; the crystal structure of the sigma1 receptor [ http://www.ncbi.nlm.nih.gov/pubmed/27042935?dopt=AbstractPlus ] suggests a trimeric structure of a single short transmembrane domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been observed to bind to these sites.        Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8157 ,  http://www.uniprot.org/uniprot/Q99720 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28106 ,  http://www.uniprot.org/uniprot/Q5BJF2 



 Agonists  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6684 [  http://www.ncbi.nlm.nih.gov/pubmed/16463398?dopt=AbstractPlus ] – Guinea pig 



 Selective agonists  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6678 [  http://www.ncbi.nlm.nih.gov/pubmed/1658302?dopt=AbstractPlus ], (  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6677 

 – 

 Antagonists  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6682 (pIC  50 7.2) [  http://www.ncbi.nlm.nih.gov/pubmed/10096443?dopt=AbstractPlus ] 



 Selective antagonists  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6679 (pIC  50 8.4) [  http://www.ncbi.nlm.nih.gov/pubmed/7901723?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6680 (pIC  50 7.4) [  http://www.ncbi.nlm.nih.gov/pubmed/8566098?dopt=AbstractPlus ] 

 – 

 Labelled ligands  [ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6683 (Agonist) 

 [ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6685 (Agonist) 



 Comments  –  The sigma2 receptor has been reported to be TMEM97 [ http://www.ncbi.nlm.nih.gov/pubmed/28559337?dopt=AbstractPlus ], a 4TM protein partner of NPC1, the Niemann‐Pick C1 protein, a 13TM cholesterol‐binding protein. 



 

 

  Comments  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1606 also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553 [  http://www.ncbi.nlm.nih.gov/pubmed/28559337?dopt=AbstractPlus ], a 4TM protein partner of NPC1, the Niemann‐Pick C1 protein, a 13TM cholesterol‐binding protein. 

  Further reading on Sigma receptors  Chu UB et al . (2016) Biochemical Pharmacology of the Sigma‐1 Receptor.  Mol. Pharmacol.  89 : 142‐53 [  https://www.ncbi.nlm.nih.gov/pubmed/26560551?dopt=AbstractPlus ] 

 Gris G et al . (2015) Sigma‐1 receptor and inflammatory pain.  Inflamm. Res.  64 : 377‐81 [  https://www.ncbi.nlm.nih.gov/pubmed/25902777?dopt=AbstractPlus ] 

 Rousseaux CG et al . (2016) Sigma receptors [  σ Rs]: biology in normal and diseased states.  J. Recept. Signal Transduct. Res.  36 : 327‐388 [  https://www.ncbi.nlm.nih.gov/pubmed/26056947?dopt=AbstractPlus ] 

 Sambo DO et al . (2018) The sigma‐1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.  Pharmacol Ther  186 : 152‐167 [  https://www.ncbi.nlm.nih.gov/pubmed/29360540 ] 

 Su TP et al . (2016) The Sigma‐1 Receptor as a Pluripotent Modulator in Living Systems.  Trends Pharmacol. Sci.  37 : 262‐278 [  https://www.ncbi.nlm.nih.gov/pubmed/26869505?dopt=AbstractPlus ] 

 Vavers E et al . (2019) Allosteric Modulators of Sigma‐1 Receptor: A Review.  Front Pharmacol  10 : 223 [  https://www.ncbi.nlm.nih.gov/pubmed/30941035 ] 

   http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=858   Overview  Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β‐tubulin, thereby interfering with the normal processes of tubulin polymer formation and disassembly.               Nomenclature  http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2638 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2639 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2752 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2641 

 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2753 



 HGNC, UniProt  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20766 ,  http://www.uniprot.org/uniprot/Q71U36 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12407 ,  http://www.uniprot.org/uniprot/P68366 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20778 ,  http://www.uniprot.org/uniprot/P07437 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20772 ,  http://www.uniprot.org/uniprot/Q13509 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20771 ,  http://www.uniprot.org/uniprot/P68371 

 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20773 ,  http://www.uniprot.org/uniprot/Q3ZCM7 



 Inhibitors  –  –  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6851 (pIC  50 9),  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6813 (pIC  50 8.2) [  http://www.ncbi.nlm.nih.gov/pubmed/21324687?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2770 (Mitotic cell cycle arrest in A431 cells) (pEC  50 8.1) [  http://www.ncbi.nlm.nih.gov/pubmed/16377187?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367 (pIC  50 8) [  http://www.ncbi.nlm.nih.gov/pubmed/16504507?dopt=AbstractPlus ],  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6798 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6809 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6824 ,  http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6785 

 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8854 (pIC  50 8.2) [  http://www.ncbi.nlm.nih.gov/pubmed/23895532?dopt=AbstractPlus ] 

 –  – 

 

 

  Further reading on Tubulins  Arnst KE et al . (2019) Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.  Med Res Rev  39 : 1398‐1426 [  https://www.ncbi.nlm.nih.gov/pubmed/30746734 ] 

 Eshun‐Wilson L. (2019) Effects of alpha‐tubulin acetylation on microtubule structure and stability. Proc Natl Acad Sci U S A  116 : 10366‐10371 [  https://www.ncbi.nlm.nih.gov/pubmed/31072936 ] 

 Gadadhar S et al . (2017) The tubulin code at a glance.  J. Cell. Sci.  130 : 1347‐1353 [  https://www.ncbi.nlm.nih.gov/pubmed/28325758?dopt=AbstractPlus ] 

 Magiera MM et al . (2018) Tubulin Posttranslational Modifications and Emerging Links to Human Disease.  Cell  173 : 1323‐1327 [  https://www.ncbi.nlm.nih.gov/pubmed/29856952 ] 

 Penna LS et al . (2017) Anti‐mitotic agents: Are they emerging molecules for cancer treatment?  Pharmacol. Ther.  173 : 67‐82 [  https://www.ncbi.nlm.nih.gov/pubmed/28174095?dopt=AbstractPlus ] 

     References  1  Agrawal  N   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21798897?dopt=AbstractPlus ]    2  Ajit  SK   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17126529?dopt=AbstractPlus ]    3  Al-Hussaini  H   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/20971825?dopt=AbstractPlus ]    4  Alduaij  W   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21378274?dopt=AbstractPlus ]    5  Alon  A   et al (  2017 ) [  https://www.ncbi.nlm.nih.gov/pubmed/28559337?dopt=AbstractPlus ]    6  ANDRADE  C  . (  1952 ) [  https://www.ncbi.nlm.nih.gov/pubmed/12978172?dopt=AbstractPlus ]    7  Balendiran  GK   et al (  2000 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10854433?dopt=AbstractPlus ]    8  Berman  DM   et al (  1996 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8756726?dopt=AbstractPlus ]    9  Bernstein  ID  . (  2000 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10720144?dopt=AbstractPlus ]    10  Blazer  LL   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21329361?dopt=AbstractPlus ]    11  Bolt  S   et al (  1993 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8436176?dopt=AbstractPlus ]    12  Caron  PC   et al (  1992 ) [  https://www.ncbi.nlm.nih.gov/pubmed/1458463?dopt=AbstractPlus ]    13  Carven  GJ   et al . (2010) Patent number: US20100266617.    14  Chuang  S   et al (  2008 ) [  https://www.ncbi.nlm.nih.gov/pubmed/18533710?dopt=AbstractPlus ]    15  Cifuentes  M   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16504507?dopt=AbstractPlus ]    16  Coelho  T  . (  1996 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8894411?dopt=AbstractPlus ]    17  Crabb  JW   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9541407?dopt=AbstractPlus ]    18  Cziraky  MJ   et al (  1993 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8137606?dopt=AbstractPlus ]    19  da Silva  AJ   et al (  2002 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11970990?dopt=AbstractPlus ]    20  De Strooper  B   et al (  1999 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10206645?dopt=AbstractPlus ]    21  Eriksson  BI   et al (  1995 ) [  https://www.ncbi.nlm.nih.gov/pubmed/7667822?dopt=AbstractPlus ]    22  Friedel  HA   et al (  1994 ) [  https://www.ncbi.nlm.nih.gov/pubmed/7528134?dopt=AbstractPlus ]    23  Furuhashi  M   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17554340?dopt=AbstractPlus ]    24  Gangjee  A   et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23895532?dopt=AbstractPlus ]    25  Garg  V   et al (  2005 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16025100?dopt=AbstractPlus ]    26  Ginaldi  L   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9593475?dopt=AbstractPlus ]    27  Glick  JL   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9748279?dopt=AbstractPlus ]    28  Goldstein  G  . (  1987 ) [  https://www.ncbi.nlm.nih.gov/pubmed/3105134?dopt=AbstractPlus ]    29  Gotti  R   et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23598032?dopt=AbstractPlus ]    30  Halk  EL   et al . (2001) Patent number: WO2001014424.    31  Hall  RD   et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23302904?dopt=AbstractPlus ]    32  Hanson  DC   et al . (2004) Human monoclonal antibodies to CTLA-4. Patent number: US6682736 B1.    33  Hertzel  AV   et al (  2009 ) [  https://www.ncbi.nlm.nih.gov/pubmed/19754198?dopt=AbstractPlus ]    34  Hohoff  C   et al (  1999 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10493790?dopt=AbstractPlus ]    35  Holmer  E   et al (  1986 ) [  https://www.ncbi.nlm.nih.gov/pubmed/3744129?dopt=AbstractPlus ]    36  Hug  C   et al (  2004 ) [  https://www.ncbi.nlm.nih.gov/pubmed/15210937?dopt=AbstractPlus ]    37  Jacobson  DR   et al (  1997 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9017939?dopt=AbstractPlus ]    38  James  LI   et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23292653?dopt=AbstractPlus ]    39  Kanji  S   et al (  2001 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11714212?dopt=AbstractPlus ]    40  Kapur  S   et al (  2001 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11463021?dopt=AbstractPlus ]    41  Kimple  RJ   et al (  2001 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11387333?dopt=AbstractPlus ]    42  Kline  J   et al (2010) [  https://www.ncbi.nlm.nih.gov/pubmed/21154117?dopt=AbstractPlus ]    43  Korman  AJ   et al . (2006)Patent number: WO2 006121168.    44  Latek  R   et al (  2009 ) [  https://www.ncbi.nlm.nih.gov/pubmed/19300198?dopt=AbstractPlus ]    45  Lee  JK   et al (  2015 ) [  https://www.ncbi.nlm.nih.gov/pubmed/26123306?dopt=AbstractPlus ]    46  Lefort  K   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17344417?dopt=AbstractPlus ]    47  Lehmann  BD   et al (  2015 ) [  https://www.ncbi.nlm.nih.gov/pubmed/25993190?dopt=AbstractPlus ]    48  Lever  JR   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16463398?dopt=AbstractPlus ]    49  Linder  ME   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17183362?dopt=AbstractPlus ]    50  Linke  R   et al (  2010 ) [  https://www.ncbi.nlm.nih.gov/pubmed/20190561?dopt=AbstractPlus ]    51  Linsley  PS   et al (  1991 ) [  https://www.ncbi.nlm.nih.gov/pubmed/1714933?dopt=AbstractPlus ]    52  Liu  Q  . (  2013 ) Fully human antibodies against human cd20. Patent number: WO20 13007052.    53  Liu  X   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21481589?dopt=AbstractPlus ]    54  Luistro  L   et al (  2009 ) [  https://www.ncbi.nlm.nih.gov/pubmed/19773430?dopt=AbstractPlus ]    55  Mach  RH   et al (  1999 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10096443?dopt=AbstractPlus ]    56  Machbub  B   et al (  1988 ) [  https://www.ncbi.nlm.nih.gov/pubmed/24248795?dopt=AbstractPlus ]    57  Maeda  K   et al (  1996 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8619847?dopt=AbstractPlus ]    58  Majava  V   et al (  2010 ) [  https://www.ncbi.nlm.nih.gov/pubmed/20421974?dopt=AbstractPlus ]    59  Mao  H   et al (  2004 ) [  https://www.ncbi.nlm.nih.gov/pubmed/15096504?dopt=AbstractPlus ]    60  Matsumoto  RR   et al (  1995 ) [  https://www.ncbi.nlm.nih.gov/pubmed/8566098?dopt=AbstractPlus ]    61  McBride  KL   et al (  2008 ) [  https://www.ncbi.nlm.nih.gov/pubmed/18593716?dopt=AbstractPlus ]    62  Mitchell  P  . (  2002 ) [  https://www.ncbi.nlm.nih.gov/pubmed/12089534?dopt=AbstractPlus ]    63  Murakami  K   et al (  1999 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10403814?dopt=AbstractPlus ]    64  Nagamatsu  I   et al (  2014 ) [  https://www.ncbi.nlm.nih.gov/pubmed/24403446?dopt=AbstractPlus ]    65  Nakase  J   et al (  2009 ) [  https://www.ncbi.nlm.nih.gov/pubmed/19398784?dopt=AbstractPlus ]    66  Nam  Y   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16530044?dopt=AbstractPlus ]    67  Narayan  S   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21324687?dopt=AbstractPlus ]    68  Ntziachristos  P   et al (  2014 ) [  https://www.ncbi.nlm.nih.gov/pubmed/24651013?dopt=AbstractPlus ]    69  Nunn  C   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16765607?dopt=AbstractPlus ]    70  Okuyama  S   et al (  1993 ) [  https://www.ncbi.nlm.nih.gov/pubmed/7901723?dopt=AbstractPlus ]    71  Ouyang  X   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16377187?dopt=AbstractPlus ]    72  Paolucci  F   et al (  2002 ) [  https://www.ncbi.nlm.nih.gov/pubmed/12383040?dopt=AbstractPlus ]    73  Penchala  SC   et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23716704?dopt=AbstractPlus ]    74  Previs  RA   et al (  2015 ) [  https://www.ncbi.nlm.nih.gov/pubmed/25388163?dopt=AbstractPlus ]    75  Puente  XS   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21642962?dopt=AbstractPlus ]    76  Reslan  L   et al (  2014 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23537278?dopt=AbstractPlus ]    77  Richieri  GV   et al (  1994 ) [  https://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus ]    78  Richieri  GV   et al (  2000 ) [  https://www.ncbi.nlm.nih.gov/pubmed/10852718?dopt=AbstractPlus ]    79  Sacchettini  JC   et al (  1989 ) [  https://www.ncbi.nlm.nih.gov/pubmed/2671390?dopt=AbstractPlus ]    80  Schiff  ML   et al (  2000 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11130074?dopt=AbstractPlus ]    81  Schmidt  HR   et al (  2016 ) [  https://www.ncbi.nlm.nih.gov/pubmed/27042935?dopt=AbstractPlus ]    82  Schroeder  F   et al (  2008 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17882463?dopt=AbstractPlus ]    83  Schroeter  EH   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9620803?dopt=AbstractPlus ]    84  SGC. I-CBP112 - a CREBBP/EP300-selective chemical probe.   85  SGC. GSK2801: A Selective Chemical Probe for BAZ2B/A bromodomains.   86  Shitara  K   et al . (2011) Patent number: US7923538 B2.    87  Siderovski  DP   et al (  2005 ) [  https://www.ncbi.nlm.nih.gov/pubmed/15951850?dopt=AbstractPlus ]    88  Sjölund  J   et al (  2008 ) [  https://www.ncbi.nlm.nih.gov/pubmed/18079963?dopt=AbstractPlus ]    89  Snow  BE   et al (  2002 ) [  https://www.ncbi.nlm.nih.gov/pubmed/11771424?dopt=AbstractPlus ]    90  Snow  BE   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9651375?dopt=AbstractPlus ]    91  Stein  R   et al (  2004 ) [  https://www.ncbi.nlm.nih.gov/pubmed/15102696?dopt=AbstractPlus ]    92  Stittrich  AB   et al (  2014 ) [  https://www.ncbi.nlm.nih.gov/pubmed/25132448?dopt=AbstractPlus ]    93  Stransky  N   et al (  2011 ) [  https://www.ncbi.nlm.nih.gov/pubmed/21798893?dopt=AbstractPlus ]    94  Strosberg  JR   et al (  2012 ) [  https://www.ncbi.nlm.nih.gov/pubmed/22445247?dopt=AbstractPlus ]    95  Structural Genomics Consortium. PFI-3: Selective chemical probe for SMARCA bromodomains.   96  Su  TP   et al (  1991 ) [  https://www.ncbi.nlm.nih.gov/pubmed/1658302?dopt=AbstractPlus ]    97  Sulsky  R   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17502136?dopt=AbstractPlus ]    98  Tanabe  H   et al (  2015 ) [  https://www.ncbi.nlm.nih.gov/pubmed/25855295?dopt=AbstractPlus ]    99  Tesmer  JJ   et al (1997) [  https://www.ncbi.nlm.nih.gov/pubmed/9108480?dopt=AbstractPlus ]    100  Tesmer  JJ   et al (  1997 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9417641?dopt=AbstractPlus ]    101  Thompson  J   et al (  1997 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9054409?dopt=AbstractPlus ]    102  Turner  EM   et al (  2012 ) [  https://www.ncbi.nlm.nih.gov/pubmed/22368763?dopt=AbstractPlus ]    103  Vicente  R  abaneda EF  et al (  2013 ) [  https://www.ncbi.nlm.nih.gov/pubmed/23899231?dopt=AbstractPlus ]    104  Vilimas  T   et al (  2007 ) [  https://www.ncbi.nlm.nih.gov/pubmed/17173050?dopt=AbstractPlus ]    105  Wang  J   et al (  1998 ) [  https://www.ncbi.nlm.nih.gov/pubmed/9748280?dopt=AbstractPlus ]    106  Wang  Y   et al (  2014 ) [  https://www.ncbi.nlm.nih.gov/pubmed/24835984?dopt=AbstractPlus ]    107  Weng  AP   et al (  2004 ) [  https://www.ncbi.nlm.nih.gov/pubmed/15472075?dopt=AbstractPlus ]    108  Westermark  P   et al (  1981 ) [  https://www.ncbi.nlm.nih.gov/pubmed/7016817?dopt=AbstractPlus ]    109  Wilson  JJ   et al (  2006 ) [  https://www.ncbi.nlm.nih.gov/pubmed/16530045?dopt=AbstractPlus ]    110  Wong  YH   et al (  1992 ) [  https://www.ncbi.nlm.nih.gov/pubmed/1347957?dopt=AbstractPlus ]    111  Yamauchi  T   et al (  2003 ) [  https://www.ncbi.nlm.nih.gov/pubmed/12802337?dopt=AbstractPlus ]    112  Young  AC   et al (1994) [  https://www.ncbi.nlm.nih.gov/pubmed/7922029?dopt=AbstractPlus ]     

